Transferrin-coated gadolinium nanoparticles as MRI contrast agent

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Medical Imaging

Background:

• Magnetic Resonance Imaging (MRI) relies on contrast agents to enhance image clarity.
• Developing novel nanoparticles for targeted drug delivery and imaging is an active area of research.
• Human serum albumin nanoparticles (HSA-NPs) offer biocompatibility and tunable properties for biomedical applications.

Purpose of the Study:

• To evaluate the contrasting properties of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) loaded HSA-NPs, with and without transferrin coating, for MRI in mice.
• To compare the efficacy of Gd-DTPA, Gd-HSA-NPs, and transferrin-coated Gd-HSA-NPs (Gd-HSA-NP-Tf) as MRI contrast agents.

Main Methods:

• HSA-NPs were conjugated with Gd-DTPA to form Gd-HSA-NPs.
• Gd-HSA-NPs were further coupled with transferrin to create Gd-HSA-NP-Tf.
• Mice underwent MRI scans before and after intravenous injection of Gd-DTPA, Gd-HSA-NP, or Gd-HSA-NP-Tf.

Main Results:

• All agents enhanced contrast in blood, heart, and liver.
• HSA-NPs achieved contrast enhancement at lower gadolinium doses compared to Gd-DTPA.
• Gd-HSA-NP-Tf showed significantly higher contrast enhancement than Gd-HSA-NP and Gd-DTPA in blood, cardiac muscle, and liver (p < 0.05).
• Gd-HSA-NP-Tf was the only agent to significantly enhance contrast in the brain (p < 0.05).

Conclusions:

• Gd-HSA nanoparticles are potential MRI contrast agents.
• Gd-HSA-NP-Tf demonstrates significant potential as a specific contrast agent for brain imaging, even with an intact blood-brain barrier.
• Gd-HSA-NP-Tf also shows promise for enhanced MRI contrast in the heart, liver, and skeletal muscle.